Google
NAMS 株価分析 — Newamsterdam Pharma Company N.V. Ordinary Shares (Healthcare >> Biotechnology)
NAMS に関するよくある質問
NAMSのROE（自己資本利益率）は？
Newamsterdam Pharma Company N.V. Ordinary SharesのROEは-31.98%です。
NAMSの配当利回りは？
Newamsterdam Pharma Company N.V. Ordinary Sharesの配当利回りは0.00%です。
NAMSの品質スコア（Quality Score）は？
当社のAIはNAMSの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NAMSは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NAMSはどのセクターに属しますか？
Newamsterdam Pharma Company N.V. Ordinary SharesはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
NAMS AI Analysis Summary
Our AI summary for NAMS: Newamsterdam Pharma Company N.V. Ordinary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -31.98%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 27.49
Price
-0.30
(-1.08%)
Day Change
|
|
|---|
NAMS, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 27.49 |
| PBV / Sector |
4.88 / 44,219.29
|
| Earning Per Share | -1.80 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
28.15 M
GREAT
|
| Average 1W Daily Value |
26.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:53 |
| Symbol | NAMS |
| Name | NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 116.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,248.76 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Gooimeer 2-35, Naarden, Netherlands, 1411 DC
Phone: 31 35 206 2971
Website: https://www.newamsterdampharma.com
Employees: 100
Sector: Healthcare >> Biotechnology
Description: NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
